NCT02754479CompletedNot Applicable
A Clinical Evaluation of the Treatment of Spider Veins on the Ankles Using a Dual Wavelength Laser Emitting 532 nm and 1064 nm Laser Energy
Cutera Inc.2 sites in 1 country4 target enrollmentStarted: June 10, 2016Last updated:
Conditions
Trial Snapshot
- Phase
- Not Applicable
- Status
- Completed
- Sponsor
- Enrollment
- 4
- Locations
- 2
- Primary Endpoint
- Physician Global Assessment of Improvement in Treated Spider Veins on the Ankles
Study Overview
Brief Summary
To evaluate the safety and effectiveness of the Excel V system for the treatment of lower extremity spider veins on the ankles.
Detailed Description
The purpose of this study is to evaluate the real-world effectiveness of the 532 nm and 1064 nm Nd:YAG lasers within the Cutera Excel V system for the treatment of lower extremity spider veins, specifically on the ankles, within a clinic setting.
Study Design
- Study Type
- Interventional
- Allocation
- Na
- Intervention Model
- Single Group
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 20 Years to 75 Years (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- •Males or females, 20 to 75 years of age (inclusive).
- •Fitzpatrick Skin Type I - III.
- •Having spider veins on at least 1 ankle measuring 2.0mm or less in diameter, linear or branching, and red, pink, blue and/or purple in color, as assessed by the investigator.
- •Having spider veins on the ankle that are appropriate for laser treatment, as assessed by the investigator.
- •Subject must be able to read, understand and sign the Informed Consent Form.
- •Subject must be willing and able to adhere to the treatment and follow-up schedule and post-treatment care instructions.
- •Wiling to have limited sun exposure for the duration of the study, including the follow-up period.
- •Willingness to have digital photographs taken of ankle spider veins and agree to use of photographs for presentation, educational or marketing purposes.
- •Agree not to undergo any other procedure for the treatment of ankle spider veins during the study.
Exclusion Criteria
- •Fitzpatrick Skin Type IV - VI.
- •Having an infection, dermatitis or a rash in the treatment area.
- •Having significant varicosities or perforator veins.
- •History of pigmentary disorders, particularly tendency for hyper- or hypo-pigmentation.
- •Systemic use of isotretinoin (Accutane®) within 6 months of study participation.
- •Excessively tanned in areas to be treated or unable/unlikely to refrain from tanning during the study.
- •In the opinion of the investigator, any physical or mental condition which might make it unsafe for the subject to participate in this study or which requires systemic therapy that could interfere with this research study.
Outcomes
Primary Outcomes
Physician Global Assessment of Improvement in Treated Spider Veins on the Ankles
Time Frame: Four weeks post final laser treatment.
Improvement in treated ankle spider veins at 4 weeks post final laser treatment (compared to baseline) as assessed by a blinded evaluators Physician Global Assessment Scale score (Min=0; 4= Max). Higher Score Indicates Better Outcome.
Secondary Outcomes
- Subject Satisfaction With Improvement in Treated Spider Veins on the Ankles(Four weeks post final laser treatment)
Investigators
Study Sites (2)
Loading locations...
Similar Trials
Recruiting
Not Applicable
The Efemoral Vascular Scaffold System (EVSS) for the Treatment of Patients With Symptomatic Peripheral Vascular Disease From Stenosis or Occlusion of the Femoropopliteal ArteryVascular DiseasesStenosisPeripheral Arterial DiseaseFemoropopliteal StenosisNCT04584632Efemoral Medical, Inc.100
Unknown
Not Applicable
Registry to Investigate the Efficacy and Safety of VenaBlock VeIn SEaling System for VaRicose Veins in SingAporeVaricose VeinsVenous RefluxChronic Venous InsufficiencyNCT04339075Singapore General Hospital30
Completed
Phase 3
A Single-arm Study to Evaluate Safety and Effectiveness of VX-548 for Acute PainPainNCT05661734Vertex Pharmaceuticals Incorporated258
Completed
Not Applicable
Vesalio NeVa VS for Symptomatic Cerebral Vasospasm Following aSAH (The VITAL Study)Cerebral VasospasmNCT03611790Vesalio30
Recruiting
Phase 3
Venetoclax+HMA+Aclarubicin Versus Venetoclax+HMA in Treatment-Naive Elderly Patients With AMLAcute Myeloid LeukemiaNCT05264883The First Affiliated Hospital with Nanjing Medical University170